Search

Astellas Pharma Inc.
  • About
    • From the CEO
    • Philosophy
      • Astellas Charter of Corporate Conduct, Group Code of Conduct
    • VISION
    • Corporate Information
      • Subsidiaries & Locations
      • Management
    • Main Products
    • Global Network
    • History
    • Board of Directors
    • Global Management Structure
    • Corporate Governance
      • Risk Management
    • Policies & Position Statements
    • Ethics & Compliance
      • Structure to Promote Ethics and Compliance
      • Primary Areas of Focus
      • Elements of Astellas’ Global Ethics & Compliance Program
      • Enhancing and Sustaining an Ethical and Compliant Culture at Astellas
    Recommended
    Corporate Strategic Plan 2021
    Read More
  • Science
    • Focus Area Approach
    • Drug Research
    • Rx+®
    • Major Pipeline
    • Data, Informatics and Analytics
    • New Modalities ~Approach for Cell and Gene Therapies~
    • Clinical Trials
    • Investigator Sponsored Research
    • Grants for Education and General Research
    Recommended
    Focus Area Approach

    The Focus Area, where we put our efforts, consists of combinations of three components: 1) biology, 2) modality/technology, 3) diseases.

    Read More
  • Partnering
    • Areas of Interest
    • Why Partner with Astellas
    • Primary Focus
      • Blindness & Regeneration
      • Mitochondria Biology
      • Genetic Regulation
      • Immuno-Oncology
    • Biology, Modality/Technology of Interest
      • Targeted Therapeutics for Auditory Regeneration
      • Autophagy
      • Bispecific Immune Cell Engager
      • Direct Reprogramming (Transdifferentiation)
      • Engineered Bacteriophage
      • Innate Immunity (Innate Lymphoid Cells)
      • Innate Immunity (Microglia)
      • Human Genetics
    • Primary Focus Candidates
    • Cell Therapy
    • Rx+® - New Healthcare Solutions Beyond Medicine
      • Chronic Disease Progression Prevention
      • Motor Function Support/Replacement
      • Digital × Neuroscience
      • Patient w/o Effective Medicines
      • Patient Outcome Maximization via Precise Surgery/Diagnosis
      • Sensory Function Support/Replacement
    • Partnering Teams
    • Get in Touch
    • For Academics
    Recommended
    Areas of Interest

    Astellas monitors Focus Areas from biology perspectives, modality/technology, and disease to identify promising areas for investment. 

    Read More
  • Sustainability
    • Astellas’ Commitment to Sustainability
    • Sustainability Approach
      • Astellas’ Sustainability Governance
      • Key Issues and Materiality
      • ISO26000
      • Astellas’ SDG Initiatives
      • United Nations Global Compact
      • Stakeholder Communications
      • Efforts for Gender Equality
      • Awards & Recognition
    • Access to Health:Our Initiatives
      • Access to Health of Astellas
      • Access to Medicines
      • Research Activities on Tuberculosis and Malaria
      • Research Activities on NTDs
      • Development of Pediatric Formulation for Schistosomiasis
      • Astellas Global Health Foundation
      • Access Accelerated
      • Action on Fistula
      • Starlight Partner Activity (Patient Support Activity)
      • Advancement of Medical Sciences
      • Participation in Global Health Innovative Technology Fund (GHIT Fund)
    • Environment
      • Environment Initiatives
      • EHS Management
        • ISO certification status of Astellas manufacturing sites
      • Environmental Action Plan and Compliance
      • Climate Change Measures
        • Scope 3 emissions (past 3 years)
      • Disclosure based on TCFD recommendations
      • Breakdown of Energy Consumption
      • Sustainable Biodiversity Initiatives
        • Biodiversity and Astellas An Enlarged Version
        • The Biodiversity Burden Index and Revenue
      • Initiatives for Resource Recycling
      • Initiatives for Preventing Pollution
        • Further information on PRTR system
      • Environmental Impact of Products and Countermeasures
      • Archive (EHS Report)
      • Environmental Accounting
        • Environment-related Investments and Expenses
      • Reporting coverage, methods, etc.
    • Astellas and Society
      • Our People
        • HR Vision, Talent and Organization Management
        • Engagement and Diversity, Equity & Inclusion
        • Occupational Health & Safety
        • Promoting Health Management
        • Major Programs (Japan)
      • Sustainability in Business Practice
        • Sustainable Procurement Initiatives
        • Research Initiatives
        • Clinical Development Initiatives
        • Technological Development and Production Initiatives
        • Distribution and Sales Initiatives
      • Respect for Human Rights
      • Community Engagement
        • Flying Star Fund
        • Employee Contributions to the Local Community
    • Governance
    • ESG Data
      • Data related ESG (2021) Environment
      • Data related ESG (2020) Social
      • ESG Data Governance
    Recommended
    Key Issues and Materiality

    To identify and prioritize the issues that are most important to society and our business, we carry out a materiality assessment and use it...

    Read More
  • News
    • News
    • Stories
    • Media Library
    Recommended
    Stories

    Stories about how Astellas members work to create innovation, as well as achieve business and sustainability strategic goals.

    Read More

Stakeholders menu

  • Investors
    • Corporate Strategic Plan 2021
    • Financial Information
    • Annual Report
    • IR Library
      • Business Results
      • Overview of R&D Pipeline
      • IR Meetings
      • Consolidated Financial Statements and Footnotes
      • Corporate Governance Materials
    • IR Calendar
    • Stock & Rating Information
      • Shareholders Meeting
      • Shareholder Return
      • Current Share Status
      • Chart
      • Issuer Rating
    • Analyst Coverage
    • Cautionary Statement
  • Careers
  • Contact Us

Common header menu

  • IMPORTANT NOTICE
  • WORLDWIDE
  • GLOBAL
  • 日本
  1. Home
  2. Investors
Important Notice

This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site.

Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.

Our Use of Cookies

In this Website, information called Cookies are stored in the PC used to browse this site, for the purpose of providing better content. Please read our Terms of Use for more information on our use of cookies. By using this site, you accept our use of cookies.

Accept
logo
Thank you for visiting the Astellas Pharma Inc. Website.
You will enter external sites beyond here.
(This link opens in a new window)
Cancel Click here to leave this site.

Investor Relations

Investors
Investors

Stock Quotes(TSE Prime: 4503)

View Stock Performance

IR News

Aug 01, 2022
Posted Financial Results for 1Q/FY2022
Jun 20, 2022
Posted Notice of Resolution
May 26, 2022
Posted Notice of Convocation of the 17th Term Annual Shareholders Meeting
Apr 27, 2022
Posted Financial Results for FY2021
Mar 09, 2022
Updated “R&D meeting” Section
Feb 28, 2022
Updated “Sustainability Meeting” Section
View All >>

Latest Materials

Financial Results (Q1/FY2022) (469KB)
Supplementary Documents (Q1/FY2022) (2,017KB)
Presentation Material for Information Meeting (Q1/FY2022) (1,106KB)

⯈ On-demand Replay of Information Meeting

Earnings call script (2,467KB)

  

 

Business Results>>

Corporate Strategic Plan 2021

Our Corporate Strategic Plan 2021 provides a path to realizing VISION in the coming years.

Read More
Financial Information

Review our consolidated business results, forecasts and financial data, etc.

Read More
Annual Report

Integrated report that includes financial and non-financial (ESG) information. Introducing Astellas' efforts for creating value for sustainable growth.

Read More
IR Library

This section contains IR related information for shareholders and investors. Various IR materials can be downloaded from here.

Read More
IR Calendar

Find our upcoming IR events.

Read More
Stock & Rating Information

Year-end dividend - March 31 Interim dividend - September 30 Note: In accordance with the Company's Articles of Incorporation, if cash dividends are not claimed for three (3) full years from the day of commencement of payment, the Company shall be relieved of the obligation to make such payment.

Read More
Analyst Coverage

List of analysts of securities companies and research companies who make recommendations and reports of Astellas' performance, etc

Read More
Cautionary Statement

The information disclosed in this part of the Astellas Website is provided for better understanding of Astellas by stakeholders including shareholders and investors, but is intended to neither solicit nor recommend the purchase of the Astellas's stock.

Read More
VISION

We introduce our VISION and common definition of VALUE, the foundation to realize our VISION.

Read More
Corporate Strategic Plan 2021

You can see the materials related to CSP 2021 here.

Read More
Major Pipeline

We introduce the progress of our clinical development projects called “R&D pipeline”. We update R&D pipeline 4 times annually in our quarterly performance reports.

Read More

Follow us on social media

Linkedin Logo Youtube Logo

Bottom footer menu

  • SITE MAP
  • PRIVACY POLICY
  • ACCESSIBILITY
  • TERMS OF USE
  • CONTACT US
  • DISASTER INFORMATION FOR EMPLOYEES
© Astellas Pharma Inc.